Noncrossing partitions under rotation and reflection
matlab 非下采样剪切波算法

matlab 非下采样剪切波算法非下采样剪切波算法是一种用于信号处理和图像压缩的算法。
它可以将信号或图像分解为多个子带,从而实现对信号或图像的分析和处理。
非下采样剪切波算法的基本原理是将信号或图像分解为不同频率的子带,然后通过对这些子带进行处理来实现对信号或图像的分析和处理。
在非下采样剪切波算法中,采用的是多尺度分解的方式,即将信号或图像分解为不同尺度的子带。
非下采样剪切波算法的核心是使用剪切波函数作为基函数进行信号或图像的分解。
剪切波函数是一种具有局部化特性的函数,它可以在时域和频域中同时具有良好的局部化特性。
通过使用剪切波函数进行信号或图像的分解,可以将信号或图像的能量集中在少数的剪切波系数上,从而实现对信号或图像的高效表示和压缩。
非下采样剪切波算法的具体步骤如下:1. 将信号或图像分解为不同尺度的子带。
首先,将信号或图像进行低通滤波和高通滤波,得到低频子带和高频子带。
然后,对低频子带进行进一步的低通滤波和高通滤波,得到更低频的子带和更高频的子带。
通过重复这个过程,可以将信号或图像分解为多个不同尺度的子带。
2. 对每个尺度的子带进行剪切波变换。
对于每个尺度的子带,使用剪切波函数进行变换,得到该尺度下的剪切波系数。
剪切波变换可以通过卷积运算实现,其中剪切波函数作为卷积核。
3. 对剪切波系数进行非下采样。
由于剪切波函数是局部化的,因此剪切波系数中只有少数的非零值。
为了提高计算效率和存储效率,可以对剪切波系数进行非下采样,即只保留其中的非零值。
4. 对剪切波系数进行处理。
对于不同的应用,可以对剪切波系数进行不同的处理。
例如,可以对剪切波系数进行阈值处理,将小于某个阈值的系数置为零,从而实现信号或图像的稀疏表示和压缩。
非下采样剪切波算法在信号处理和图像压缩中具有广泛的应用。
它可以用于信号的降噪和去除干扰,图像的去噪和增强,以及图像的压缩和传输等方面。
非下采样剪切波算法通过将信号或图像分解为多个子带,并对子带进行处理,可以实现对信号或图像的高效分析和处理,从而提高信号处理和图像压缩的效果。
matlab 非下采样剪切波算法

matlab 非下采样剪切波算法Matlab 非下采样剪切波算法非下采样剪切波变换(Non-Subsampled Contourlet Transform,简称NSCT)是一种用于图像处理和图像压缩的多尺度分析方法。
它在图像处理领域中得到了广泛的应用,特别是在图像增强、图像恢复和图像压缩等方面。
NSCT 是一种重构算法,它通过将图像分解成不同尺度的子带来实现多尺度分析。
与传统的小波变换相比,NSCT 不仅能够提供更多的图像细节信息,还具有更好的图像压缩性能。
其关键思想是通过非下采样滤波器组来进行图像分解,然后通过剪切波算法将图像信号转换为非下采样的低频信号和多个高频子带信号。
NSCT 算法的主要步骤包括分解、滤波、剪切和重构四个部分。
首先,将输入的图像通过非下采样滤波器组进行分解,得到低频子带和多个高频子带。
然后,对每个高频子带进行剪切,保留其中的重要信息,去除冗余和噪声。
剪切的过程可以通过将每个高频子带划分为不同的频率区域,并对每个频率区域进行截断来实现。
最后,通过逆变换将剪切后的子带进行重构,得到最终的图像。
NSCT 算法的优点在于能够提供更好的图像细节保留和更好的压缩性能。
其通过将图像分解为多个子带,并对每个子带进行剪切,可以有效地去除图像中的冗余和噪声,从而提高图像质量。
同时,NSCT 还具有较好的图像压缩性能,可以在保持图像质量的同时实现较高的压缩比。
在实际应用中,NSCT 算法可以广泛用于图像增强和图像恢复。
通过对图像进行多尺度分析和剪切,可以提高图像的细节保留和图像质量。
例如,在医学图像处理中,NSCT 可以用于提取图像中的病变区域和细节信息,从而帮助医生进行诊断和治疗。
此外,在图像压缩领域,NSCT 还可以用于实现高效的图像压缩算法,节省存储空间和传输带宽。
Matlab 非下采样剪切波算法是一种用于图像处理和图像压缩的多尺度分析方法。
通过将图像分解为多个子带,并对每个子带进行剪切,可以提高图像的细节保留和图像质量。
2016年04月急性冠脉综合征治疗新药临床研究指导原则.(英文版)

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom1 April 2016 1 EMA/CHMP/207892/20152 Committee for medicinal products for human use (CHMP)3 Guideline on clinical investigation of new medicinal 4products for the treatment of acute coronary syndrome 5(CPMP/EWP/570/98) 6Draft7 Draft agreed by Cardiovascular Working PartyFebruary 2016 Adopted by CHMP for release for consultation1 April 2016 Start of public consultation 27 April 2016 End of consultation (deadline for comments)31 October 2016 8 This guideline replaces 'Points to consider on the clinical investigation of new medicinal products for the 9 treatment of acute coronary syndrome (ACS) without persistent ST segment elevation' 10 (CPMP/EWP/570/98). 1112 Comments should be provided using this template . The completed comments form should be sent to CVSWPSecretariat@ema.europa.eu .13Keywords Acute coronary syndrome, STE-ACS, NSTE-ACS, guideline, CHMP1415Table of contents16Executive summary (4)171. Introduction (background) (4)182. Scope (5)193. Legal basis and relevant guidelines (5)204. Choice of efficacy criteria (endpoints) (6)214.1. All-cause mortality and CV mortality (6)224.2. New myocardial infarction (6)234.3. Revascularisation (6)244.4. Unstable angina pectoris necessitating hospitalisation (6)254.5. Stent thrombosis (6)264.6. Stroke (7)274.7. Left ventricular function and heart failure (7)284.8. Composite endpoints (7)294.9. Endpoints in fibrinolysis studies (7)305. Methods to assess efficacy (how to measure the endpoints) (8)315.1. Mortality (8)325.2. New myocardial infarction (8)335.3. Revascularisation (8)345.4. Unstable angina pectoris necessitating hospitalisation (8)355.5. Stent thrombosis (8)365.6. Ventricular function and heart failure (9)375.7. Angiographic endpoints (9)386. Selection of patients (9)396.1. Study population (9)406.1.1. STE-ACS (ST elevation acute coronary syndrome) (9)416.1.2. NSTE-ACS (Non-ST elevation acute coronary syndrome) (9)426.1.3. Unstable angina (9)436.2. Inclusion criteria for the therapeutic studies (10)446.3. Exclusion criteria for the therapeutic studies (10)456.4. Risk Stratification (10)466.5. Special populations (11)476.5.1. Older patients (11)487. Strategy and design of clinical trials (11)497.1. Clinical pharmacology (11)507.2. Therapeutic exploratory studies (12)517.2.1. Objectives (12)527.2.2. Design (12)537.3. Confirmatory Therapeutic Studies (12)547.3.1. Objectives (12)557.3.2. Background therapy (12)567.3.3. Choice of comparator (13)577.3.4. Duration of clinical studies (13)587.3.5. Analyses and subgroup analysis (13)598. Safety aspects (14)608.1. Bleedings (14)618.2. All-cause mortality (15)628.3. Thrombocytopenia (15)638.4. Rebound effect (15)648.5. Effects on laboratory variables (15)658.6. Effects on concomitant diseases (15)66References (16)6768Executive summary6970Two CHMP Guidelines have been previously developed to address clinical investigations of new71medicinal products for the treatment of acute coronary syndrome (ACS): (I) the CHMP points toconsider (PtC) on the clinical investigation of new medicinal products for the treatment of acute7273coronary syndrome without persistent ST-segment elevation (CPMP/EWP/570/98), published in 2000 74[1], and (II) the CHMP PtC on the clinical development of fibrinolytic products in the treatment of75patients with ST segment elevation myocardial infarction (CPMP/EWP/967/01), published in 2003 [2].76Since their finalisation, major developments have taken place in the definitions, diagnosis,77interventions and management of ACS, as reflected in the relevant European Society of Cardiology78(ESC) clinical practice guidelines (3, 4). Currently, an update of the above mentioned CHMP Guidelines 79is considered necessary to take these new developments into consideration based on literature review 80and experience gained with medicinal products intended for treatment during the acute phase and81beyond. The present update includes the following changes: 1) guidance addressing both ST-segment 82elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction83(NSTEMI), as well as unstable angina (UA), 2) update in their definitions, 3) risk stratification using84different scoring systems, 4) investigated endpoints, and 5) clinical developments of new medicinal85products beyond the acute stage, including agents other than antiplatelets and anticoagulants.1. Introduction (background)8687Cardiovascular diseases are currently the leading cause of death in industrialized countries and also 88expected to become so in emerging countries by 2020 [3, 4]. Among these, coronary artery disease 89(CAD) is the most prevalent manifestation and is associated with high mortality and morbidity. ACS 90has evolved as a useful operational term to refer to any constellation of clinical symptoms that are91compatible with acute myocardial ischemia. It encompasses (STEMI), NSTEMI, and UA.92ACS represents a life-threatening manifestation of atherosclerosis. It is usually precipitated by acute 93thrombosis induced by a ruptured or eroded atherosclerotic coronary plaque, with or without94concomitant vasoconstriction, causing a sudden and critical reduction in blood flow. In the complex95process of plaque disruption, inflammation was revealed as a key pathophysiological element. Non-96atherosclerotic aetiologies are rare e.g. such as arteritis and dissection.97The leading symptom of ACS is typically chest pain. Patients with acute chest pain and persistent (>20 min) ST-segment elevation have ST-elevation ACS (STE-ACS) that generally reflect an acute total9899coronary occlusion. Patients with acute chest pain but without persistent ST-segment elevation have 100rather persistent or transient ST-segment depression or T-wave inversion, flat T waves, pseudo-101normalization of T waves, or no ECG changes. At presentation, based on the measurement of102troponins, it is possible to further discriminate between the working diagnosis of non-ST-elevation ACS 103(NSTE-ACS) and unstable angina.104NSTE-ACS is more frequent than STE-ACS [5] with an annual incidence around 3 per 1000 inhabitants, 105but varying between countries [6]. Hospital mortality is higher in patients with STEMI than among 106those with NSTEMI (7% vs. 3–5%, respectively), but at 6 months the mortality rates are very similar 107in both conditions (12% and 13%, respectively) [5,7,8]. Long term follow-up shows that death rates 108were higher among patients with NSTE-ACS than with STE-ACS, with a two-fold difference at 4 years[8]. This difference in mid- and long-term evolution may be due to different patient profiles, since 109110NSTE-ACS patients tend to be older with more co-morbidities, especially diabetes and renal failure.2. Scope111112The aim of this guideline is to provide guidance when performing trials to develop medicinal products 113in the management of ACS. The primary goals of therapy for patients with ACS are to:1. Treat acute, life-threatening complications of ACS, such as serious arrhythmias, pulmonary 114115oedema, cardiogenic shock and mechanical complications of acute myocardial infarction (AMI). [9] 1162. Reduce the amount of myocardial necrosis that occurs in patients with AMI, thus preserving 117left ventricular (LV) function, preventing heart failure (HF), and limiting other cardiovascular118complications.1193. Prevent major adverse cardiac events like death, non-fatal myocardial infarction (MI), andneed for urgent revascularization.120121The focus in this Guideline concerns mainly the medical treatment of ACS (treatment goals 2 and 3). 122The choice of interventional procedures [percutaneous coronary intervention (PCI) or coronary artery 123bypass graft CABG)] falls outside the scope of this guideline.3. Legal basis and relevant guidelines124125This guideline has to be read in conjunction with the introduction and general principles and parts I 126and II of the Annex I to Directive 2001/83 as amended.127Pertinent elements outlined in current and future EU and ICH guidelines, should also be taken into 128account, especially those listed below:129•Dose-Response Information to Support Drug Registration (ICH E4; CPMP/ICH/378/95).130•Statistical Principles for Clinical Trials (ICH E9; CPMP/ICH/363/96).131•Choice of Control Group and Related Issues in Clinical Trials (ICH E10; CPMP/ICH/364/96).132•Points to consider on an Application with 1) Meta-analyses 2) One pivotal study133(CPMP/EWP/2330/99).134•Points to consider on multiplicity issues in clinical trials (CPMP/EWP/908/99).135•Investigation of subgroups in confirmatory clinical trials (EMA/CHMP/539146/2013).136•The Extent of Population Exposure to Assess Clinical Safety for Drugs (ICH E1A;137CPMP/ICH/375/95).138•Pharmacokinetic Studies in Man (3CC3A).139•Studies in Support of Special Populations: Geriatrics (ICH E7 CHMP/ICH/379/95) and related Q&A 140document (EMA/CHMP/ICH/604661/2009).141•Note for Guidance on the Investigation of Drug Interactions (CPMP/EWP/560/95).142•Reporting the Results of Population Pharmacokinetic Analyses (CHMP/EWP/185990/06).143•Reflection paper on the extrapolation of results from clinical studies conducted outside the EU to 144the EU-population (EMEA/CHMP/EWP/692702/2008).145•Draft Guideline on clinical investigation of medicinal products for the treatment of chronic heart 146failure (EMA/392958/2015 )•Guideline on clinical investigation of medicinal products for the treatment of acute heart failure147148(CPMP/EWP/2986/03 Rev. 1)4. Choice of efficacy criteria (endpoints)149150Definitions of clinical endpoints in confirmatory trials should be in line with the relevant clinical151guidelines to facilitate interpretation of the results, to allow comparisons across clinical studies and to 152extrapolate to clinical practice. Endpoints should be centrally adjudicated by a blinded committee. The 153following endpoints are relevant to the investigation of efficacy in patients with ACS.4.1. All-cause mortality and CV mortality154155As one of the goals of treatment of ACS is reduction of mortality, this is an important endpoint to156measure. There is an ongoing debate around the use of all-cause versus cardiovascular mortality in 157cardiovascular (CV) trials. All cause mortality is the most important endpoint in clinical trials for the 158estimation of the benefit-risk balance of a drug, in particular when investigating newer medicinal159products with possible safety issues. On the other hand, CV mortality is more specifically linked to the 160mode of action of CV medicinal products/intervention and is especially relevant when the earliest part 161of the follow up is assessed. The choice is also dependent on the objective of the study i.e. in non-162inferiority trials, CVmortality may be preferred while in superiority trials all cause mortality is usually 163used. In fibrinolysis studies, all cause mortality is preferred (see section 4.9).164As such, one of the two mortality endpoints should be included as a component of the primary165endpoint, with the other investigated as a key secondary endpoint.4.2. New myocardial infarction166167New onset MIis a relevant endpoint in studies of ACS and should always be investigated. The definition 168of MI has evolved through the years; at the time of drafting of this Guideline, the third universal169definition of MI is applicable [10]. Criteria of MI are the same as those used to define the index event 170(see below).4.3. Revascularisation171172Some clinical trials have included revascularization endpoints (PCI or CABG) as part of the primary 173composite with conflicting results [11, 12]. Such endpoints are considered more relevant tointerventional studies, and in the scope of this Guideline, their inclusion as a primary endpoint should 174175be clearly justified and their assessment pre-defined and systematically assessed.4.4. Unstable angina pectoris necessitating hospitalisation176177Unstable angina has been investigated in ACS clinical trials. Due to the varying definitions used, the 178associated subjectivity and the influence of local clinical practice, this endpoint is not encouraged to be 179included in the composite primary endpoint.4.5. Stent thrombosis180181Stent thrombosis (ST) is a rare event that can have fatal consequences. ST has been captured in some 182registration studies, but not consistently in the primary endpoint (PEP). The investigation of ST as part 183of the primary endpoint is not encouraged due to the uncertainty of the clinical relevance of all184captured events, except for the "definite" subcategory. Another category identified by the timing isintra-procedural stent thrombosis (IPST), which is a rare event indicating the development of occlusive 185186or non-occlusive new thrombus in or adjacent to a recently implanted stent before the PCI procedure is187completed. Some recent studies [13,14] show that these events may be of prognostic value. As such they should also be collected and presented as secondary endpoint but not included in the analysis of 188189ST.4.6. Stroke190191Stroke should be defined by a generally accepted definition [15]. Clinical studies in ACS have used192non-fatal stroke in the primary endpoint , including any types of strokes. However it is preferred to193include only ischemic strokes in the primary endpoint, as this is the true measure of efficacy;194haemorrhagic stroke should be included as a safety endpoint. An ischaemic stroke with haemorrhagic195conversion should be considered as “primary ischaemic”. The subgroup of “undefined strokes” should196be as small as possible in order to be able to properly assess the effect of the study treatment. In case 197all types of strokes are included in the primary endpoint, a sensitivity analysis including only ischemic198stroke should be submitted.4.7. Left ventricular function and heart failure199Some medicinal products such as modulators of reperfusion injury or inflammation, or gene/cell200201therapy are developed to improve myocardial function and reduce the occurrence of HF. In these202cases, measurement of myocardial function could be a relevant endpoint to investigate the mechanismof action. In phase III studies, these endpoints can be investigated as secondary endpoints to support 203204the clinical endpoints. Occurrence of HF should be considered as a clinical endpoint in phase III studies205aimed at showing benefit in long-term cardiovascular outcome. All-cause mortality and long term206follow-up are mandatory in studies with novel interventions.4.8. Composite endpoints207Due to the rather low incidence of cardiovascular events during the follow-up period after the acute 208209phase of the ACS, composite endpoints consisting of relevant components are acceptable, both as210primary and secondary endpoints. The composite of CV death, non-fatal MI and non-fatal stroke (Major211Adverse Cardiovascular Events, [MACE]) has commonly been used in registration studies, with non-212fatal strokes showing limited contribution to the results. As such, it is preferred to investigate the213composite of death and non-fatal MI in confirmatory studies; non-fatal ischaemic stroke could beincluded in the composite if justified. Sometimes different definitions of MACE are being used with214215novel therapies [16], that should be justified when used in place of MACE. The inclusion of less216objective and clinically derived outcomes in the same composite is generally not encouraged, as they217may either drive the efficacy or dilute the results. In case these endpoints are included they have to be218stringently defined, and adjudicated. Each component of the primary composite endpoint should be219analysed as secondary endpoint.220The net clinical benefit that includes both benefit and safety issues of the studied drug may be used as221a secondary endpoint to be evaluated if it contributes to the discussion on the benefit-risk balance of222the studied drug.4.9. Endpoints in fibrinolysis studies223224In fibrinolysis studies, angiographic studies using the TIMI (Thrombolysisi in Myocardial Infarction)perfusion grades as evaluation criteria are often used. However, complete recanalization cannot be 225226considered as a surrogate for survival when assessing fibrinolytic drugs, as some medicinal productsproviding higher complete recanalization rates than alteplase, failed to demonstrate additional survival 227228benefit. For this reason, all cause mortality is the most relevant endpoint or a combined endpoint as 229previously discussed (see 4.1). Secondary endpoints such as heart failure hospitalisations, left230ventricular function, ventricular arrhythmias, the need for rescue recanalization (emergent and/or231planned) should also be considered and justified.5. Methods to assess efficacy (how to measure the232endpoints)2335.1. Mortality234235Definition of CV death should be clearly defined, in line with acceptable standards [17]. It is mandatory 236to report and centrally adjudicate all mortality data where survival is an endpoint of the study.237Assessment of cardiovascular mortality will require censoring of other “types” of mortality, which may 238complicate its interpretation, in particular when non-CV deaths are in high proportion.5.2. New myocardial infarction239240The diagnostic of MI is based on the detection of a rise and/or fall of cardiac biomarker values241[preferably cardiac troponin (cTn)] with at least one value above the 99th percentile upper reference 242limit (URL). All MIs should be collected and also classified by their different sub types (i.e,243spontaneous, secondary to an ischemic imbalance, related to PCI, related to ST or CABG) [10]. This is 244particularly important considering the different prognostic values of each type of MI. For the same 245reason and to support the clinical relevance of post procedural MIs, these events should be presented 246with higher cut-off values (≥ 5 and ≥10x upper level of normal ULN, in case of CK-MB or ≥70x ULN of 247cTn) [18]. These higher cut-off values can also help in diagnosing MIs in the setting of elevated248baseline biomarkers, which is a problematic situation. In such cases, serial measurements of the249biomarkers are necessary, in addition to new ECG changes or signs of worsening of cardiac function, 250e.g. HFor hypotension [18].5.3. Revascularisation251252The underlying cause of revascularization should be identified: restenosis, ST or disease progression. 253In the latter case target vessel revascularization (TVR) could be included. Early target lesion eventsafter revascularization (before 30 days) are more likely to be caused by an angiographic complication 254255and should preferably be included as safety endpoint (see ST).5.4. Unstable angina pectoris necessitating hospitalisation256257When investigated, robust definitions should be employed. In order to support the seriousness of the 258event it should also be shown that it has led to a revascularisation procedure. Since a medicinalproduct that prevents death and/or new MI might result in more patients suffering from UA, the259260analysis of this endpoint should take into account censoring issues as well.5.5. Stent thrombosis261262ST should be collected and classified as definite, probable and possible in line with acceptable263definitions [19]. In addition, the timing of ST should be documented (acute, sub-acute, late and very 264late), as risk factors and clinical sequels differ with timing.5.6. Ventricular function and heart failure265266Investigation of cardiac function should follow state of the art methods. This can include among others 267measurement of ventricular function by isotopic method and/or by cardiac magnetic resonance imaging 268and/or echocardiography. Investigation of HFshould follow the relevant CHMP guidelines.5.7. Angiographic endpoints269270Angiograms should undergo central blinded reading. In principle, the rate of TIMI 3 flow (complete 271revascularization) of the infarct related artery at 90 minutes is considered the most relevant272angiographic endpoint, as it has been shown to correlate with an improved outcome in terms of273mortality and left ventricular function. An earlier evaluation of the patency pattern (i.e. 30 and 60274minutes) may provide important information on the speed of recanalization. Whatever is the time-point 275selected as primary outcome, it must be properly justified and pre-specified in the clinical trial.6. Selection of patients2766.1. Study population277The definition of the different ACS subtypes should be based on current guidelines/universal definition 278279of MI including STEMI and NSTEMI as well as UA [3, 4, 10].6.1.1. STE-ACS (ST elevation acute coronary syndrome)280281In patients with acute chest pain and persistent (>20 min) ST-segment elevation on ECG the282diagnostic of STE-ACS is made [3]. This condition generally reflects an acute total coronary occlusion.Most patients will ultimately develop an ST-elevation myocardial infarction (STEMI) with the criteria of 283284acute myocardial infarction described before [see 5.2].6.1.2. NSTE-ACS (Non-ST elevation acute coronary syndrome)285286In patients with acute chest pain but no persistent ST-segment elevation the diagnostic of NSTE-ACS is 287made [4]. ECG changes may include transient ST-segment elevation, persistent or transient ST-288segment depression, T-wave inversion, flat T waves or pseudo-normalization of T waves or the ECG 289may be normal. The clinical spectrum of non-ST-elevation ACS (NSTE-ACS) may range from patients 290free of symptoms at presentation to individuals with ongoing ischaemia, electrical or haemodynamic 291instability or cardiac arrest. The pathological correlate at the myocardial level is cardiomyocyte292necrosis (NSTEMI) or, less frequently, myocardial ischaemia without cell loss (UA). Currently, cardiac 293troponins play a central role in establishing a diagnosis and stratifying risk, and make it possible to 294distinguish between NSTEMI and UA[4].6.1.3. Unstable angina295296Unstable angina (UA) is defined as myocardial ischemia at rest or minimal exertion in the absence of 297cardiomyocytes necrosis, i.e. without troponin elevation. Among NSTE-ACS population, the higher298sensitivity of troponin has resulted in an increase in the detection of MI [4]; the diagnosis of UAis less 299frequently made.6.2. Inclusion criteria for the therapeutic studies300301Inclusion of both STEMI and NSTEMI and/or NSTE-ACS patients in the same clinical trial (or not)302should be justified based on the mechanism of action of the investigated product and the proposed 303time of intervention. If both subgroups are investigated in the same trial, both subgroups should be 304well represented. For interventions aimed at post-acute and longer term phases (secondary305prevention or plaque stabilisation) it may be justified to address both conditions in the same clinical 306trial. Time of inclusion of the patients in relation to the index event should be set and adequately307discussed a priori.308Patients with unstable angina represent a different risk category and prognosis that necessitates309different interventions than NSTEMI patients. However, during the acute presentation of NSTE-ACS it may be difficult to discriminate NSTEMI from UA so both groups have been included in some clinical 310311studies. In general, the investigation of interventions in these patients is encouraged, but preferably in 312separate clinical trials.If fibrinolysis is considered, inclusion criteria should be in line with the current treatment guidelines 313314concerning the inclusion for fibrinolysis [3].6.3. Exclusion criteria for the therapeutic studies315316If the patients do not fulfil the above criteria for ACS they should be excluded from the ACS studies. 317Other life-threatening conditions presenting with chest pain, such as dissecting aneurysm,318myopericarditis or pulmonary embolism may also result in elevated troponins and should always be 319considered as differential diagnoses [4].320If drugs interfering with the haemostatic system are tested, patients with a significant risk of bleeding 321(e.g. recent stroke, recent bleeding, major trauma or surgical intervention) and/or a propensity to 322bleed (e.g. thrombocytopenia, clotting disturbances, intracranial vascular diseases, peptic ulcers,323haemophilia) should be excluded from participation in the clinical studies.324Attention should be paid to the time elapsed between a previous application of antiplatelet or325anticoagulant acting agent beforehand and the administration of study drug (e.g. the pharmacokinetic 326[PK] and even more importantly, the pharmacodynamic [PD] half-life of these previously administered 327drugs).328For reasons of generalisability of the study results to the future target population it is strongly advised 329not to define the exclusion criteria too narrow, i.e. polymorbid patients (e.g. renal and/or hepatic330impairment, heart failure), should not automatically be excluded from the main therapeutic clinical 331trials.332When fibrinolysis is considered, exclusion criteria for fibrinolysis should be strictly respected [3].6.4. Risk Stratification333334In clinical trials, the ability of the therapy to demonstrate a treatment effect may depend on the335underlying risk and expected event rates. Enrichment strategies are sometimes used in trials to obtain 336the required number of events with a reasonable time in specific subgroups who are likely to exhibit a 337higher event rate than the overall target population and potentially larger treatment effect. In thatcase, it has to be shown that the results of this enriched study population can be extrapolated to the 338339general population.。
非极大值一致 nms的工作流程

非极大值一致 nms的工作流程下载提示:该文档是本店铺精心编制而成的,希望大家下载后,能够帮助大家解决实际问题。
文档下载后可定制修改,请根据实际需要进行调整和使用,谢谢!本店铺为大家提供各种类型的实用资料,如教育随笔、日记赏析、句子摘抄、古诗大全、经典美文、话题作文、工作总结、词语解析、文案摘录、其他资料等等,想了解不同资料格式和写法,敬请关注!Download tips: This document is carefully compiled by this editor. I hope that after you download it, it can help you solve practical problems. The document can be customized and modified after downloading, please adjust and use it according to actual needs, thank you! In addition, this shop provides you with various types of practical materials, such as educational essays, diary appreciation, sentence excerpts, ancient poems, classic articles, topic composition, work summary, word parsing, copy excerpts, other materials and so on, want to know different data formats and writing methods, please pay attention!非极大值抑制(NMS)的工作流程在计算机视觉领域,非极大值抑制(NMS)是一种常用的技术,用于处理目标检测算法输出中的重叠框。
利用非抽样Contourlet变换的抗旋转攻击水印算法

(. p r et P yi ad l t n I om tn n i ei ,hnl n e i,hnl ,ha r760 , h a 1 Deat no hs s n Ee r i n ra o E gn r gSagu U i rt Sag oSani200C i ; m f c co c f i e n o v sy u n 2Shoo C m u r c ne n T ho g ,ia n e i, in 10 1C i ) .col o p t Si cad e nl yXd n ir (X ' 707 , n f e e c o i U v sv a ha
第7 第7 卷 期 21 0 2年 7 月
中国利 做
C IAS E C P P R HN CIN E A E
V 1 o7 o. N . 7
JJ 2 1 u. 02
利用非抽样 C nor t ot l 变换的抗旋转攻击水印算法 ue
赵 杰 ,杨滨峰 ,肖 斌 2
( 商洛学院物理与电子信息工程 系,陕西商洛 76o ;2 西安电子荆 大学计算机学院,西安 707 ) 1 . 200 . 赦 10 1
足不可见性条件下对旋转、加噪、剪切和JE P G压缩等常见处理有较强的鲁棒性。 关键词:数字水印;非抽 ̄Jn ul变换 自适应;角度校正 ot rt o e 中匿 予 类号:T 3 1 P9. 4 猷示 }志码:A 譬 号:29 — 7321) — 53 6 荤《 05 28(02 7 02 — 0
t l iaetec nmdcin b t e ecp bly a dr b s s.h tr r d piey e e d c odn eh ma o ei n t o l it ewen i m h o mp re t it n u mes tewaemak i a a t l mb d e ac r igt t u n i i o S v d oh
改进的非数据辅助前向反馈符号定时恢复算法

算 法 在 高性 噪 比时 自噪声 较 大 ,尤其 是 当成 形 与 匹 配 滤
波 器 的滚 降 系 数 较 小时 更 加 明 显 ,且 周期 跳 转 现 象 并 未 能 消 除[ 8 1 。
中心差分格式 隐式 -回复

中心差分格式隐式-回复中心差分格式(Central Difference Scheme)是数值分析中一种常用的差分格式,常用于求解偏微分方程的数值解。
该格式的特点是在时间和空间上都采用中心差分的方式,能够提供较高的数值稳定性和精度。
在本文中,将详细介绍中心差分格式的基本原理、求解步骤以及应用范围。
中心差分格式的基本原理是利用有限差分法来近似求解偏微分方程。
偏微分方程通常描述了物理系统的变化过程,通过将连续的问题离散化为离散的数值问题,可以方便地使用计算机进行求解。
为了理解中心差分格式的原理,我们首先需要了解差分近似。
通过将时间和空间上的连续变量离散化,得到一系列有限的格点。
偏导数可以通过求取两个相邻格点之间的差商来近似计算。
在求解偏微分方程时,中心差分格式使用了中心差分来近似偏导数。
对于空间上的差分,中心差分将函数在当前格点和相邻格点上的函数值取平均,得到了近似的一阶导数。
对于时间上的差分,中心差分则利用了当前时刻和前一时刻的函数值来近似计算。
这种方式可以提供更高的数值稳定性,因为它能够考虑到当前时刻的变化以及前一时刻的信息。
中心差分格式的隐式形式是指使用未知量的未来值来近似计算当前值。
这样的形式可以提供更高的数值稳定性,但却需要通过一种迭代算法来求解。
下面我们将详细说明中心差分格式的求解步骤:1. 确定求解区域以及网格格点数量。
根据具体问题的要求,确定网格的大小和分布。
2. 初始化边界条件和初始条件。
根据实际情况,设置边界条件和初始条件。
3. 迭代求解。
通过迭代算法逐步更新未知量的值,直到达到收敛条件。
a) 在时间上进行迭代。
对于每个时间步长,更新时间点上未知量的值。
这里使用中心差分来近似计算。
b) 在空间上进行迭代。
对于每个空间点,更新其值。
这里同样使用中心差分来近似计算。
这个过程可以通过构建一个线性方程组来实现。
c) 判断是否达到收敛条件。
通常可以通过比较当前迭代结果和上一次迭代结果之间的差异来进行判断。
operation would result in non-manifold bodies

operation would result in non-manifold bodies在计算机图形学和几何建模领域,非流形体是指在三维空间中形状的一种特殊类型。
一个非流形体具有一个或多个不符合流形特性的区域。
流形是指一个无边界、表面光滑、内部无孔洞的物体,而非流形体则违反了这些性质。
非流形体在计算机图形学中经常出现,因为在建模和形状编辑过程中,一些操作可能会导致这种类型的物体。
下面是一些可能导致非流形体的操作:1. 重叠面:当一个物体的两个面共享相同的边或边集时,就会出现重叠面。
这可能是由于复制、移动或变形等操作导致的,会导致一个或多个非流形体形成。
2. 孔洞:一个非流形体可能有一个或多个孔洞,即在物体内部形成的空心区域。
这可能是由于布尔运算(如取交集、取并集)或其他形状编辑操作导致的。
3. 自交:自交是指一个物体的某个部分与其它部分相交。
这可能是由于旋转、拉伸、挤压等操作导致的,会导致非流形体的产生。
4. 嵌塞:嵌塞是指一个物体的某个部分被另一个物体或其自身部分所包围。
这可能是由于复制、移动、布尔运算等操作导致的。
5. 物体边界:非流形体的边界可能会有额外的不连续部分,即在其中一个顶点出现了一个无界的半边。
这种情况可以由于顶点的合并、分裂、删除等操作引起。
非流形体的存在可能会影响后续的计算和渲染过程。
例如,非流形体在进行体现场计算(CSG)和有限元分析时可能会导致错误的结果。
此外,在图形渲染过程中,非流形体可能会导致阴影、光照、纹理映射等效果的不准确或意外变化。
为了处理非流形体,通常需要进行修复操作,将其转换为流形体。
修复非流形体的方法有很多,一些常用的方法包括:1. 网格替代:通过重新生成一个流形网格替代非流形网格。
这可能涉及到重建表面或拓扑结构,以确保生成的网格符合流形特性。
2. 清理操作:通过一系列操作,例如顶点合并、边合并、面合并等,来清理非流形体中的不连续和重叠部分。
3. 网格修剪:通过删除非流形体中的不规则部分或孔洞,使其成为一个流形体。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
a r X i v :m a t h /0510447v 3 [m a t h .C O ] 30 O c t 2005Noncrossing Partitions Under Rotation and ReflectionDAVID CALLAN LEN SMILEY Department of Statistics Department of Mathematical Sciences University of Wisconsin-Madison University of Alaska Anchorage 1300University Ave 3211Providence Drive Madison,WI 53706-1532Anchorage AK 99508callan(at) smiley(at) October 30,2005Abstract We consider noncrossing partitions of [n ]under the action of (i)the reflection group (of order 2),(ii)the rotation group (cyclic of order n)and (iii)the rota-tion/reflection group (dihedral of order 2n).First,we exhibit a bijection from rotation classes to bicolored plane trees on n edges,and consider its implications.Then we count noncrossing partitions of [n ]invariant under reflection and show that,somewhat surprisingly,they are equinumerous with rotation classes invariant under reflection.The proof uses a pretty involution originating in work of Germain Kreweras.We conjecture that the “equinumerous”result also holds for arbitrary partitions of [n ].1IntroductionA noncrossing partition of [n ]={1,2,...,n }is one for which no quadruple a <b <c <d has a,c in one block and b,d in another.This implies that if the elements of [n ]are situated around a circle with 1→2→3→···→n →1forming a cycle,and neighboring elements within each block are joined by line segments,then no line segments cross one another (see figure below).The map i →i +1(mod n )on [n ]induces a map—the rotation operator R —on partitions πof [n ].Equivalence under repeated application of R divides them into rotation classes:A (π)={R i (π)}i ≥1.The complement of a partition πof [n ]is C (π):=n +1−π(elementwise).It is easy to check that C ◦R =R −1◦C and so the complement operation permutes rotation classes.We say a partition πis self-complementary if C (π)=πand a rotation class A is self-complementary if C (A )=A .As we will see,a self-complementary rotation class need not contain any self-complementary partitions.The operations rotation and complementation both preserve the noncrossing (NC)property of partitions.In particular,a rotation class consists entirely of NC partitions if it contains a single one.A NC rotation class may be represented by a polygon diagram with the labels removed,we’ll call it an NC Polygon (or Partition)Pattern (NCPP). ••123456polygon diagram of the NC partitionpolygon diagram of its rotation class 134-2-56:labels fixed in place is an NCPP:no labels,rotate at willClearly,a NC partition is self-complementary if its labeled polygon diagram is invariant when flipped across a vertical line,and a NC rotation class is self-complementary if its plane polygon pattern is achiral,that is,invariant when flipped over (across any line).A bicolored plane tree is a plane tree (no root,no labels)in which each vertex is colored white or yellow (say)in such a way that adjacent vertices get different colors.The color of one vertex determines that of all the others (see Figure 5).We exhibit a bijection from NC rotation classes (n points)to bicolored plane trees (n edges)in §2.We count self-complementary NC partitions in §3and show they are equinumerous with self-complementary NC rotation classes,equivalently,achiral NC polygon patterns in §4.Remarks,figures,and a conjecture comprise §5.The Appendix contains enumerations and tables.The enumeration of bicolored plane trees (A054357)has been significantly generalized in [2].We note that (scaled)Shabat polynomials [1,4]are also counted by A054357.2BijectionThe bijection from NC polygon diagrams to bicolored binary trees is depicted in the Figure below.In forming the polygon diagram of a NC partition,the convex hull of each block of size k forms a k -sided yellow polygon even for k =1,2by liberal interpretation of “polygon”as illustrated.The polygons are disjoint because the partition is noncrossing.Ignoring the labels and considering the configuration of polygons only up to rotation,it represents an NC polygon pattern(NCPP).38An NC polygon diagram with superimposed bicolored plane treepolygon sides ↔tree edgesThe bijection is clear:place a vertex in each region of the circle,both yellow and white.Join vertices in adjacent regions by edges.Then allow each vertex to inherit the color of the region it’s in to get the desired bicolored plane tree.As for invertibility,the “star”tree with yellow leaves joined to a white center corresponds to the NCPP all ofwhose polygons are of the degenerate one-sided type.Otherwise the tree has a non-leafbelow.yellow vertex and its inverse is formed recursively as illustratedthe polygon surrounding an internal yellow vertex;recursivelyconstruct polygons for the trees T i on their corresponding arcsThere are two immediate consequences of this bijection.Thefirst one is a special case of Theorem10in[2].•The Catalan numbers(A000108)count bicolored plane trees with a distinguished edge.This is because the positioning of the labels on the circle can be captured by associating an edge in the tree with label1,say thefirst tree edge encoun-tered travelling clockwise from1around the polygon incident with1.Thus the distinguished-edge bicolored plane trees on n edges are in correspondence with or-dinary NC partitions of[n],counted by C n[12].•On NC partitions,as well as on circular NC partitions,the statistics“#singletons”and“#adjacencies”have the same distribution,in fact a symmetric joint distribu-tion.This is due to the correspondences yellow leaf↔singleton block,and white leaf↔adjacency,that is,two consecutive elements of[n]in the same block.(Of course consecutive is taken here in the circular sense,so n and1are considered con-secutive.)The symmetry of the joint distribution holds for unrestricted partitions too[5].3Counting Self-Complementary NC PartitionsUsing paths from (0,0)with Upsteps (1,1)and Downsteps (1,−1)(see,e.g.,[7]),we will show that the number of self-complementary NC partitions of [n ]is n ⌊n/2⌋ .There is a bijection from Dyck n -paths (Quadrant 1,ending at (2n,0))to NC partitions of [n ]that sends #peaks to #blocks.Given a Dyck n -path,number its upsteps left to right and then give each downstep the number of its matching upstep.The numbers on each descent (maximal sequence of contiguous downsteps)form the blocks of the corresponding NC partition.. d d d d d d d d d d d d d d d d d d d d d d d d ........................................................................................................................145387962111210123456789101112number downsteps,each with the number of its matching upstep •••••••••••••••••••••••••Partition downstep labels by descents to get1−4−53−87−962−11−1210,a noncrossing partition with arc diagram123456789101112Under this bijection,peak downsteps correspond to largest block elements,and downsteps returning the path to ground level correspond to smallest elements in maximal blocks (a maximal block is one whose arcs would get wet if it rained,here there are 3such:1,269,1012).Theorem 1.The number of self-complementary NC partitions of [n ]is |A n |= n ⌊n/2⌋ .Proof We give a bijective proof for n even.(The case n odd is similar and is omitted.)So suppose n =2m .The right hand side clearly counts paths of m upsteps and m downsteps (balanced m -paths).Now a NC partition πof [2m ]induces a partition τof [m ]by intersecting its blocks with [m ].For τi a block of τ,setτior τi ∪last form is permissible only ifτi is a maximal block ofτ(elseπwould have a crossing). So self-complementary NC partitionsπof[2m]correspond to NC partitionsτof[m]in which each maximal block may(or not)be marked:a mark onτi indicating thatτi∪τi are separate blocks ofπ.Using the NC partition↔Dyck path correspondence above,these marked objects correspond in turn to Dyck m-paths with returns(to ground level)available for marking.Returns split a Dyck path into its components(Dyck subpaths whose only return is at the end).Flip over each component that terminates at a marked return to obtain a balanced m-path. This is the desired bijection from self-complementary NC partitions of[2m]to balanced m-paths.4Counting Achiral NC Polygon PatternsTheorem2.The set A n of achiral NC Polygon Patterns(or self-complementary NC rotation classes)of[n]is equinumerous with the set of self-complementary NC partitions of[n],and hence|A n|= n⌊n/2⌋ .To prove this,recall two related operations on NC partitions[8,11]defined using polygon diagrams as illustrated in Figures1,2,3below.In both cases,new vertices(in blue)interleave the old vertices(in black)but their labelings differ.The new labels are then formed into maximal blocks subject only to:new polygons are disjoint from the old ones.It is clear from their defining diagrams thatH2=R−1,T2=I,T=CHand it is not hard to see that T R=R−1T and hence,by induction,T R i=R−i T for all i.The following result is key to the bijection establishing the Theorem.Proposition1.CT=TRCProof H2=R−1⇒H=R−1H−1⇒CT=R−1T C=T RC.For n≥3,H=R and we note in passing that the operations C,T,H,R on NC partitions of[n]generate a dihedral group D2n(of4n elements)with presentation H,C: H2n=C2=I,CHC−1=H−1 .Figure1:NC parti-tionπby polygonsFigure2:πwith H(π)Figure3:πwith T(π)Next we define the notion of complement order on partitions in achiral NC rotation classes.Suppose A∈A n andπis a partition in A.Then C(π)∈A(because A is achiral) and so C(π)=R i(π)for some i≥1(i=n will do if C(π)=π).Define the complement order ofπto be the minimal such i≥1.Lemma1.(i)An achiral rotation class A contains at most2self-complementary partitions. (ii)If|A|is odd,then A contains exactly one self-complementary partition.(iii)If|A|is even,then either every partition in A has even complement order or ev-ery partition in A has odd complement order.In the former case,A contains2self-complementary partitions;in the latter case,none.The proof is deferred.Theorem2will follow from this lemma if we can show that, among even-cardinality achiral NC rotation classes A in A n,there are just as many associated with even complement order as with odd.(Of course,|A|even implies n even.) We claim the transpose T is a bijection,indeed an involution,that interchanges these two families.To see this,first suppose that A∈A n has even cardinality,say|A|=2s,and π∈A has even complement order,say C(π)=R2mπ.Then,using Proposition1,C(Tπ)=T R Cπ=T R2m+1π=R−(2m+1)Tπ=R2s−2m−1(Tπ)and Tπhas odd complement order.The other direction is similar,the desired bijection is established,and Theorem2follows.Proof of Lemma1Suppose a rotation class A contains a self-complementary partition π.Then the complement of every other element of A is given byCR iπ=R−i Cπ=R−iπ(1)Now suppose R iπ∈A is also self-complementary.It follows from(1)that R2iπ=π.Set t=|A|so that R jπ=π⇒t|j.Hence t|2i.If t is odd,then t|i and R iπ=π,implying thatπis the only self-complementary partition in A.If t is even,say t=2s,then s|i and R iπis one of R sπand R2sπ=π. These facts establish part(i)and the“at most one”half of part(ii).For the“at least one”half of part(ii),suppose|A|is odd.Takeπ∈A.Since A is achiral,Cπ=R kπfor some k and so the complement of each element of A is given by CR iπ=R k−iπ.If k is even,then i=k/2makes R iπself-complementary.On the other hand,if k is odd,say k=2ℓ+1and|A|=2s+1,then i=ℓ−s makes R iπself-complementary.This establishes part(ii).For part(iii),let t:=|A|be even.First,suppose someπ∈A has even complementary order k:C(π)=R kπ.Then C(R iπ)=R k−iπ=R k−2i R iπand the powers of R that fix R iπare all≡k−2i(mod t)and hence even.Thus every element of A has even complementary order and R iπis self-complementary for i=k/2and i=(k+t)/2. Similarly,if some elementπof A has odd complementary order,then they all do,and the equation C(R iπ)=R iπhas no solution.5Concluding Remarks1.The transpose defined in Figure3above coincides with the restriction to NC par-titions of the conjugate[5]defined on all partitions of[n].In particular,the algo-rithmic definition of conjugate given in[5]provides a practical way to compute the transpose.2.An analog of Theorem2appears to hold for arbitrary partitions:the number ofself-complementary rotation classes of partitions on[n]coincides with the number of self-complementary partitions of[n].The proof of Lemma1goes through unchanged(it does not use the NC property).Unfortunately,the conjugate does not serve in the role of transpose to interchange the two relevant families in this larger setting,and it would be interesting to find an extension of the transpose that does.3.Figures 4and 5show the 28bijective pairs (by geographic position)of NCPP’s and bicolored plane trees for n =6.To avoid clutter,only one leaf per tree displays its color.Singleton (yellow)leaves are colored “0”;adjacency (white)leaves are colored“1”.Figure 4:NC Patterns,n=6Figure 5:Bicolored 6-edge plane treesAppendix:Enumeration Formula for Unlabeled NC Parti-tions and Bicolored Plane Trees(almost ab initio)The partitions of the set[n]={1,2,...,n}(the decompositions of[n]as a union of pairwise-disjoint,non-empty subsets)are counted by the sequence of Bell numbers. If the elements of[n]are regarded as the set of labels of n otherwise indistinguishable objects,the unlabeled enumeration of partitions of these objects is the same as counting the partitions of the integer n.Non-crossing partitions(cf.Introduction)are beautiful,and have been closely studied. Motzkin noted[9,last sentence]that the number of labeled non-crossing partitions,as a function of n,satisfies the Catalan recurrence,and in fact these are counted by the sequence of Catalan numbers.In the unlabeled case,there are two candidate sequences:the leading one regards the circle as embedded in a plane with the points evenly spaced and counts non-crossing partitions inequivalent under rotations of the circle(these are the NC Partition Patterns); the second identifies two partition classes counted in thefirst which are the same after reflection across a diameter of the circle(we might call these classes chirally inequivalent NC Partition Patterns).Motzkin[9,penultimate sentence]gave the beginning of the latter sequence as1,2,3,6,9,24.This contains an(almost certainly clerical)error:the value for n=5should be10,not9.Because the“label/unlabel”paradigm has been invoked,the sequence NCP P(n)fits into one of at least two competing enumerative analogies:if the circle is discarded en-tirely,then Bell numbers:partitions of n::Catalan numbers:NCP P(n);if only the NC requirement is relaxed,then Bell:possibly crossing partition patterns(A084423):: Catalan:NCP P(n).The essential fact needed in the direct enumeration of NC partition patterns was proven by V.Reiner[10]:if n=kd,k≥2,and the points are labelled a1,a2,...,a n,then the number of NC partitions having the property“a i and a j are in the same part if and only if a i+d(mod n)and a j+d(mod n)are in the same part”is 2d d .We refer to such NC partitions as d-clickable(suggested by analogy to clicking a physical dial with n positionsthrough d positions and arriving at the same partition).Reiner gives two proofs;for theconvenience of the reader we informally describe the bijection used in one of ing k distinct colors for the a’s,relabel the points consecutively to make k monocolor intervals subscripted1,...,d.Consider the’unwrapped’doubly-infinite sequence...a d−1,a d,a1,a2,...,a d,A1,...,A d,a1,a2.........,a d−1,a d,a1,...(here font/case is used to denote color).On the circle,find a part of the partition,say of size p,consisting entirely of a consecutive set of points.This will always be possible for an NC partition.In a set L place the subscript of thefirst(clockwise)element in the chosen part,and in a set R the subscript of the last.This will be possible if the part is proper.Remove all elements with subscripts equal to those in this part from the doubly-infinite sequence and from the circle.The resulting sequence still consists of equal length monocolor intervals in the k colors,and(after equispacing the remaining points on the circle)is(d−p)-clickable.Repeat the process until no such proper part remains to be chosen,at which time the sets L and R are equinumerous,but otherwise arbitrary, subsets of[d].The number of ways of specifying such an L and R is easily seen to be 2d d .To reverse the process,consider a copy of the original doubly-infinite sequence and for each element of L(resp.R)place a Left(resp.Right)parenthesis to the left(resp. right)of each symbol in the sequence with subscript equal to this element.When L and R are exhausted the partition may be decoded from the parenthesized string in the usual manner.Figure6displays a partition of[24]which is3-,6-,and12-clickable(we use partitioning walls instead of polygons for viewability).The generator(click)σof Z24may be thought of as a rotation of the diagram through2π/24leaving the labels in place.The pictured partition is then afixed point ofσ3i,i=0,...,7.As one of the 63 3-clickables,it isafixed point of all of these,includingσ3,σ9,σ15,andσ21.As one of the superset of 126 6-clickables,(cf Figure7),it may not be invariant under those4rotations,but it must be afixed point ofσ6,andσ18,while as one of the 2412 12-clickables,it need only be an invariant of{σ12,σ0}.These considerations generalize succinctly in the following enumeration.11Figure6:A3-clickable partitionFigure7:A6-clickable partition,not 3-clickableTheorem3.The number of NC Partition Patterns of n points on a circle is1n+1 2n n + 1≤i<ni|nφ(ni,and these numberφ(nThe enumeration of bicolored plane trees predates,and thus confirms,Theorem3. The number of(free)plane trees on n edges is known to beFPT(n):=1d) 2d d −(C n−C n−12,see(A002995).Here and below C m is understood to be0if m is not an integer,and the term involving Catalan numbers is an integer because C m is odd iff the integer m has the form2k−1.The size of a plane tree is its number of edges.The subtrees of a vertex are the plane trees obtained by deleting the vertex and its incident edges.A center of a plane tree is a vertex v that minimizes max{size(T):T a subtree of v}.A plane tree either has a unique center or two adjacent centers.Deleting the connecting edge in the latter case leaves two ordered trees.Symmetry then implies that the number of bicolored plane tree on n edges is2FPT(n)−C n−1n NC Dihedral Classesor NCPP’s(A054357+A001405)/2112033605102847491906093361708728112904174288252 132943219128093924 1532639922106701098900 1738252382653829213244836 1946553116328215300164015272 2158270669241583304162078812492 References[1]N.Adrianov and A.Zvonkin,Composition of plane trees,Acta Applicandae Mathe-maticae52,Numbers1-3,July1998,239–245.[2]Miklos Bona,Michel Bousquet,Gilbert Labelle and Pierre Leroux,Enumeration ofm-ary cacti,Advances in Applied Mathematics,24(2000),22–56.[3]Michel Bousquet,Quelques r`e sultats sur les cactus planaires,Annales des SciencesMathematiques du Quebec,24(2000)No.2.p.107-128.14[4]Mireille Bousquet-M´e lou,Combinatorics in Bordeaux,www.mat.univie.ac.at/ slc/wpapers/s34bordeaux。